Celcuity Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$226.5MTTM through 30 Jun 2026
Free Cash Flow -$192.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-360.3%ROE
-47.0%ROA
Balance Sheet Health
Debt / Equity6.04x
Current Ratio12.31x
Net Debt-$63.6Mnet cash position
Cash & Equivalents$182M
Quality Metrics
Altman Z-Score2.12
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$4.30TTMFY2025: $-3.79
Dividend
No dividend
Capital Allocation
R&D Spend$143M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Therapeutics Development | $0 | 0.0% | View detailsFDA accepted the NDA for gedatolisib in HR+/HER2- PIK3CA wild-type advanced breast cancer with a PDUFA goal date of July 17, 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.